Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
-
* Corresponding author: Alfonso Duenas-Gonzalez alduenas@prodigy.net.mx
Molecular Cancer 2005, 4:22 doi:10.1186/1476-4598-4-22
Accesses
- Last 30 days: 259 accesses
- Last year: 2139 accesses
- All time: 11951 accesses
Cited by
BioMed Central: 6 citations
|
Review
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer Shundong Cang, Yuehua Ma, Delong Liu Journal of Hematology & Oncology 2009, 2:22 (1 June 2009) |
|
Research article
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer Florian R Fritzsche, Wilko Weichert, Annika Röske, Volker Gekeler, Thomas Beckers, Carsten Stephan, Klaus Jung, Katharina Scholman, Carsten Denkert, Manfred Dietel, Glen Kristiansen BMC Cancer 2008, 8:381 (19 December 2008) |
|
Review
Aleksander M Grabiec, Paul P Tak, Kris A Reedquist Arthritis Research & Therapy 2008, 10:226 (17 October 2008) |
|
Research
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo Blanca Segura-Pacheco, Berenice Avalos, Edgar Rangel, Dora Velazquez, Gustavo Cabrera Genetic Vaccines and Therapy 2007, 5:10 (24 September 2007) |
|
Research
Erick de la Cruz-Hernández, Enrique Pérez-Cárdenas, Adriana Contreras-Paredes, David Cantú, Alejandro Mohar, Marcela Lizano, Alfonso Dueñas-González Virology Journal 2007, 4:18 (26 February 2007) |
|
Review
Epigenetic aberrations and cancer Miryam Ducasse, Mark A Brown Molecular Cancer 2006, 5:60 (8 November 2006) |